Financhill
Sell
39

SNY Quote, Financials, Valuation and Earnings

Last price:
$48.12
Seasonality move :
1.14%
Day range:
$48.45 - $48.80
52-week range:
$45.80 - $60.12
Dividend yield:
4.52%
P/E ratio:
17.32x
P/S ratio:
2.49x
P/B ratio:
1.48x
Volume:
1.5M
Avg. volume:
2.2M
1-year change:
-5.42%
Market cap:
$118.7B
Revenue:
$47.9B
EPS (TTM):
$2.80

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SNY
Sanofi SA
$11.7B $1.00 -17.69% 92.33% $62.57
BNTX
BioNTech SE
$173.2M -$2.26 23.21% -34.69% $136.68
BPMC
Blueprint Medicines
$171.3M -$0.53 24.15% -36.72% $126.87
NVAX
Novavax
$149.2M -$0.11 -64.49% -82.16% $13.43
REGN
Regeneron Pharmaceuticals
$3.3B $8.55 -7.35% -30.58% $728.55
VIGL
Vigil Neuroscience
-- -$0.47 -- -9.62% $9.52
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SNY
Sanofi SA
$48.55 $62.57 $118.7B 17.32x $2.20 4.52% 2.49x
BNTX
BioNTech SE
$111.00 $136.68 $26.7B 191.55x $0.00 0% 9.00x
BPMC
Blueprint Medicines
$129.36 $126.87 $8.4B -- $0.00 0% 14.75x
NVAX
Novavax
$6.97 $13.43 $1.1B 2.63x $0.00 0% 0.95x
REGN
Regeneron Pharmaceuticals
$570.59 $728.55 $61.6B 14.53x $0.88 0.31% 4.62x
VIGL
Vigil Neuroscience
$8.07 $9.52 $376.6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SNY
Sanofi SA
20.53% -0.268 15.28% 0.26x
BNTX
BioNTech SE
1.53% 1.572 1.45% 9.86x
BPMC
Blueprint Medicines
53.13% 2.692 6.79% 2.62x
NVAX
Novavax
180.06% 1.446 16.39% 1.84x
REGN
Regeneron Pharmaceuticals
6.33% 0.047 2.89% 3.90x
VIGL
Vigil Neuroscience
-- 10.653 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SNY
Sanofi SA
$8.1B $2.6B 6.79% 8.47% 22.36% $2.2B
BNTX
BioNTech SE
$104.2M -$562M -3.86% -3.91% -225.11% -$1.5B
BPMC
Blueprint Medicines
$146.6M -$41.1M -23.09% -49.13% 12.78% -$56.3M
NVAX
Novavax
$612.2M $515.5M -- -- 83.91% -$187.1M
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M
VIGL
Vigil Neuroscience
-- -$23.5M -- -- -- -$24.2M

Sanofi SA vs. Competitors

  • Which has Higher Returns SNY or BNTX?

    BioNTech SE has a net margin of 17.65% compared to Sanofi SA's net margin of -227.46%. Sanofi SA's return on equity of 8.47% beat BioNTech SE's return on equity of -3.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    72.76% $0.80 $101.3B
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
  • What do Analysts Say About SNY or BNTX?

    Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand BioNTech SE has an analysts' consensus of $136.68 which suggests that it could grow by 23.14%. Given that Sanofi SA has higher upside potential than BioNTech SE, analysts believe Sanofi SA is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 3 0
    BNTX
    BioNTech SE
    14 5 0
  • Is SNY or BNTX More Risky?

    Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.318%.

  • Which is a Better Dividend Stock SNY or BNTX?

    Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or BNTX?

    Sanofi SA quarterly revenues are $11.2B, which are larger than BioNTech SE quarterly revenues of $192.3M. Sanofi SA's net income of $2B is higher than BioNTech SE's net income of -$437.5M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 9.00x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.49x 17.32x $11.2B $2B
    BNTX
    BioNTech SE
    9.00x 191.55x $192.3M -$437.5M
  • Which has Higher Returns SNY or BPMC?

    Blueprint Medicines has a net margin of 17.65% compared to Sanofi SA's net margin of 0.33%. Sanofi SA's return on equity of 8.47% beat Blueprint Medicines's return on equity of -49.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    72.76% $0.80 $101.3B
    BPMC
    Blueprint Medicines
    98.13% $0.01 $729.9M
  • What do Analysts Say About SNY or BPMC?

    Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.93%. Given that Sanofi SA has higher upside potential than Blueprint Medicines, analysts believe Sanofi SA is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 3 0
    BPMC
    Blueprint Medicines
    2 15 1
  • Is SNY or BPMC More Risky?

    Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

  • Which is a Better Dividend Stock SNY or BPMC?

    Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or BPMC?

    Sanofi SA quarterly revenues are $11.2B, which are larger than Blueprint Medicines quarterly revenues of $149.4M. Sanofi SA's net income of $2B is higher than Blueprint Medicines's net income of $496K. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 14.75x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.49x 17.32x $11.2B $2B
    BPMC
    Blueprint Medicines
    14.75x -- $149.4M $496K
  • Which has Higher Returns SNY or NVAX?

    Novavax has a net margin of 17.65% compared to Sanofi SA's net margin of 82.81%. Sanofi SA's return on equity of 8.47% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    72.76% $0.80 $101.3B
    NVAX
    Novavax
    97.75% $2.93 $94.5M
  • What do Analysts Say About SNY or NVAX?

    Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 92.66%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 3 0
    NVAX
    Novavax
    3 2 1
  • Is SNY or NVAX More Risky?

    Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Novavax has a beta of 2.691, suggesting its more volatile than the S&P 500 by 169.079%.

  • Which is a Better Dividend Stock SNY or NVAX?

    Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or NVAX?

    Sanofi SA quarterly revenues are $11.2B, which are larger than Novavax quarterly revenues of $626.3M. Sanofi SA's net income of $2B is higher than Novavax's net income of $518.6M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Novavax's PE ratio is 2.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 0.95x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.49x 17.32x $11.2B $2B
    NVAX
    Novavax
    0.95x 2.63x $626.3M $518.6M
  • Which has Higher Returns SNY or REGN?

    Regeneron Pharmaceuticals has a net margin of 17.65% compared to Sanofi SA's net margin of 26.7%. Sanofi SA's return on equity of 8.47% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    72.76% $0.80 $101.3B
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About SNY or REGN?

    Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 27.68%. Given that Sanofi SA has higher upside potential than Regeneron Pharmaceuticals, analysts believe Sanofi SA is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 3 0
    REGN
    Regeneron Pharmaceuticals
    14 7 0
  • Is SNY or REGN More Risky?

    Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

  • Which is a Better Dividend Stock SNY or REGN?

    Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Regeneron Pharmaceuticals offers a yield of 0.31% to investors and pays a quarterly dividend of $0.88 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or REGN?

    Sanofi SA quarterly revenues are $11.2B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Sanofi SA's net income of $2B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Regeneron Pharmaceuticals's PE ratio is 14.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 4.62x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.49x 17.32x $11.2B $2B
    REGN
    Regeneron Pharmaceuticals
    4.62x 14.53x $3B $808.7M
  • Which has Higher Returns SNY or VIGL?

    Vigil Neuroscience has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat Vigil Neuroscience's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SNY
    Sanofi SA
    72.76% $0.80 $101.3B
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
  • What do Analysts Say About SNY or VIGL?

    Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Vigil Neuroscience has an analysts' consensus of $9.52 which suggests that it could grow by 18.02%. Given that Sanofi SA has higher upside potential than Vigil Neuroscience, analysts believe Sanofi SA is more attractive than Vigil Neuroscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    SNY
    Sanofi SA
    5 3 0
    VIGL
    Vigil Neuroscience
    0 8 0
  • Is SNY or VIGL More Risky?

    Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Vigil Neuroscience has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SNY or VIGL?

    Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Vigil Neuroscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Vigil Neuroscience pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SNY or VIGL?

    Sanofi SA quarterly revenues are $11.2B, which are larger than Vigil Neuroscience quarterly revenues of --. Sanofi SA's net income of $2B is higher than Vigil Neuroscience's net income of -$22.4M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Vigil Neuroscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus -- for Vigil Neuroscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SNY
    Sanofi SA
    2.49x 17.32x $11.2B $2B
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock